olmesartan has been researched along with Kidney Diseases in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horino, T; Ichii, O; Shimamura, Y; Terada, Y | 1 |
| Dohi, Y; Hirota, H; Isaka, N; Ito, M; Kato, T; Kimura, G; Kojima, M; Machida, H; Makino, K; Miyagawa, K; Mizubayashi, R; Mizuno, O; Nakatani, K; Okamoto, S; Okubo, S; Okura, T; Takeuchi, M | 1 |
| Arozal, W; Arumugam, S; Gounder, VK; Harima, M; Nomoto, M; Pitchaimani, V; Suzuki, K; Thandavarayan, RA; Watanabe, K | 1 |
| Clifford, CR; Feldman, A; Liang, C; Parker, C; Walker, AM | 1 |
| Al-Harbi, MM; Al-Harbi, NO; Alabidy, AD; Almukhallafi, AF; Imam, F; Iqbal, M; Nadeem, A; Sayed-Ahmed, MM | 1 |
| Kamide, K; Maekawa, Y; Ohishi, M; Onishi, M; Rakugi, H; Takeya, Y; Tatara, Y; Yamamoto, K | 1 |
| Chen, R; Eisner, C; Hu, X; Huang, Y; Kopp, JB; Leelahavanichkul, A; Mizel, D; Schnermann, J; Star, RA; Wright, EC; Yan, Q; Yuen, PS; Zhou, H | 1 |
| Kashihara, N; Nagasu, H; Sasaki, T; Satoh, M; Tomita, N; Yorimitsu, D | 1 |
| Kim, HJ; RodrÃguez-Iturbe, B; Sato, T; Vaziri, ND | 1 |
| Fukuda, M; Ichikawa, T; Ito, A; Kato, Y; Kimura, G; Miura, T; Miyagi, S; Mizuno, M; Shirasawa, Y; Tomonari, T; Wakamatsu-Yamanaka, T; Yoshida, A | 1 |
| Kumagai, H; Matsubara, H; Oda, T; Ohshima, N; Senda, M; Tadano, H; Takechi, H; Uchida, T; Watanabe, A; Yamamoto, K | 1 |
| Fujita, K; Funahashi, T; Hibuse, T; Hiuge, A; Kihara, S; Kumada, M; Kurata, A; Kuriyama, H; Maeda, N; Nishizawa, H; Ohashi, K; Okada, T; Shimomura, I; Sonoda, M; Yasui, A | 1 |
1 review(s) available for olmesartan and Kidney Diseases
| Article | Year |
|---|---|
[Recent advance in kidney and hypertension research].
Topics: Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Agonists; Catheter Ablation; Cerebrovascular Circulation; Chronic Disease; Diabetic Nephropathies; Drug Therapy, Combination; Evidence-Based Medicine; Fumarates; Humans; Hypertension; Imidazoles; Kidney; Kidney Diseases; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2012 |
2 trial(s) available for olmesartan and Kidney Diseases
| Article | Year |
|---|---|
Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension; Imidazoles; Kidney Diseases; Male; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Tetrazoles; Young Adult | 2013 |
Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Drug Therapy, Combination; Female; Hawaii; Humans; Hypertension; Imidazoles; Imidazolidines; Kidney; Kidney Diseases; Male; Middle Aged; Proteinuria; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2010 |
9 other study(ies) available for olmesartan and Kidney Diseases
| Article | Year |
|---|---|
Renal thrombotic microangiopathy caused by bevacizumab.
Topics: Adenocarcinoma of Lung; Aged; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Bevacizumab; Biopsy; Humans; Imidazoles; Kidney Diseases; Male; Proteinuria; Tetrazoles; Thrombotic Microangiopathies | 2018 |
Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Blood Urea Nitrogen; Cholesterol; Creatinine; Daunorubicin; Glutathione Peroxidase; Imidazoles; Kidney; Kidney Diseases; Male; Matrix Metalloproteinase 2; NF-E2-Related Factor 2; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles; Triglycerides | 2014 |
Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Cohort Studies; Death, Sudden, Cardiac; Female; Follow-Up Studies; Humans; Imidazoles; Kidney Diseases; Male; Middle Aged; Retrospective Studies; Risk; Tetrazoles; United States; Young Adult | 2014 |
Olmesartan attenuates tacrolimus-induced biochemical and ultrastructural changes in rat kidney tissue.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcineurin Inhibitors; Imidazoles; Kidney Diseases; Kidney Tubules, Proximal; Male; Mitochondria; Podocytes; Rats; Rats, Wistar; Tacrolimus; Tetrazoles | 2014 |
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chronic Disease; Desoxycorticosterone; Disease Models, Animal; Disease Progression; Fibrosis; Genetic Predisposition to Disease; Glomerulonephritis; Heart Diseases; Hydralazine; Hypertension; Imidazoles; Infusion Pumps, Implantable; Infusions, Subcutaneous; Kidney; Kidney Diseases; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Nephrectomy; Sodium Chloride, Dietary; Species Specificity; Telemetry; Tetrazoles; Time Factors; X-Ray Microtomography | 2010 |
Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Dihydropyridines; Drug Therapy, Combination; Hydrochlorothiazide; Imidazoles; Kidney Diseases; Oxidative Stress; Rats; Rats, Inbred SHR; Tetrazoles; Vascular Diseases | 2011 |
Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Progression; Glomerulosclerosis, Focal Segmental; Hypertension; Imidazoles; Kidney; Kidney Diseases; Male; NF-E2 Transcription Factor; NF-kappa B; Oxidative Stress; Proteinuria; Random Allocation; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Tetrazoles; Thiobarbituric Acid Reactive Substances | 2011 |
Angiotensin receptor blockers shift the circadian rhythm of blood pressure by suppressing tubular sodium reabsorption.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Blood Pressure; Circadian Rhythm; Creatinine; Female; Glomerular Filtration Barrier; Humans; Imidazoles; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Male; Middle Aged; Natriuresis; Sodium; Tetrazoles; Young Adult | 2011 |
Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation.
Topics: Adiponectin; Adipose Tissue; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Cells, Cultured; Female; Gene Expression Regulation; Imidazoles; Kidney Diseases; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Obesity; Oxidative Stress; Plasminogen Activator Inhibitor 1; Reactive Oxygen Species; RNA, Messenger; Serum Amyloid A Protein; Signal Transduction; Tetrazoles; Tumor Necrosis Factor-alpha | 2006 |